Beijing Chengnuo Medical Technology

Beijing Chengnuo Medical Technology is a Chinese healthcare company that operates as both a major distributor of high-end medical devices and an innovative biotech developer. Founded in 1999, the company initially focused on introducing international cardiovascular technologies, such as Abiomed's Impella heart pump, to the Chinese market. More recently, through its Chineo Medical brand, it has advanced a pipeline of novel cell therapies, most notably its proprietary ScTILs (Super circulating TIL-like cells) platform which modifies peripheral blood-derived T cells to treat solid tumors. The company maintains a significant presence in China with over 15 regional branches and has been involved in several high-profile medical device partnerships and investments, including a stake in Shanghai NewMed Medical. Despite its commercial success, the company has faced legal challenges, including intellectual property disputes with international partners.